In vitro Activities of A-56619 (Difloxacin) and A-56620, Two Aryl Fluoroquinolones
- 1 January 1988
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 34 (4) , 298-307
- https://doi.org/10.1159/000238583
Abstract
The in vitro activities of A56619 (difloxacin) and A-56620, two newer quinolones, have been compared with the activities of ciprofloxacin, ofloxacin, ceftazidime and netilmicin. A total of 782 clinical, bacterial isolates were employed. Minimal inhibitory concentrations (MICs) were determined under standard conditions with all isolates and, for 100 isolates against difloxacin and A-56620, with variation of agar pH and bacterial inoculum size. On a weight-for-weight basis, ciprofloxacin and A-56620 were the most active agents against Enterobacteriaceae (MIC90 = 0.03 and 0.12 mg/l, respectively). Difloxacin was the least active quinolone, particularly against Proteus, Morga-nella and Providencia spp. Except for ceftazidime, all agents were highly active against staphylococci, but difloxacin and ofloxacin were somewhat less active against Staphylococcus saprophytics. The streptococcal isolates were moderately sensitive to the quinolones, difloxacin being least active. Haemophilus influenzae and Neisseria gonorrhoeae were extremely susceptible to all the quinolones; nearly all isolates were inhibited by the lowest concentrations of the agents that were employed in the study (0.03 mg/l). The quinolones all showed moderate activity against Bacteroides fragilis. The activities of difloxacin and A-56620 were affected little by inoculum size. Difloxacin showed lower activity against most isolates at pH 8.0 as compared to the activity at pH 7.4 and 6.8. A-56620 was minimally influenced by pH variation.Keywords
This publication has 12 references indexed in Scilit:
- CLASSIFICATION OF COAGULASE-NEGATIVE STAPHYLOCOCCI IN THE DIAGNOSTIC LABORATORYActa Pathologica Microbiologica Scandinavica Section B Microbiology, 2009
- Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscessAntimicrobial Agents and Chemotherapy, 1986
- In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolonesAntimicrobial Agents and Chemotherapy, 1986
- In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolonesAntimicrobial Agents and Chemotherapy, 1986
- In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1986
- In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1986
- In vitro evaluation of A-56619 and A-56620, two new quinolonesAntimicrobial Agents and Chemotherapy, 1986
- In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620Antimicrobial Agents and Chemotherapy, 1985
- In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1983
- THE N/F AND OXI/FERM SYSTEMS FOR IDENTIFICATION OF OXIDATIVE‐FERMENTATIVE GRAM‐NEGATIVE RODS: A COMPARATIVE STUDYActa Pathologica Microbiologica Scandinavica Series B: Microbiology, 1982